$WST

Ex-Dividend Reminder: West Pharmaceutical Services, Heritage Financial and Entegris

West Pharmaceutical Services (WST), Heritage Financial Corp (HFWA), and Entegris Inc (ENTG) are all set to trade ex-dividend on January 28, 2026, for their upcoming quarterly dividends. Investors can expect a slight price adjustment for each stock, corresponding to their respective dividend payouts. The article provides current dividend amounts, ex-dividend dates, and historical dividend charts, encouraging investors to review past performance for stability when assessing future yield.

Original reporting
Nasdaq · BNK Invest
Published Jan 26, 2026, 2:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 26, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$WST
Neutral
high confidence
Mentioned
$WST · $HFWA · $ENTG
alphai data visualization · based on Nasdaq
Decision brief

The 30-second read

$WSTNeutralMed
01

Why it matters

Ex-dividend dates typically lead to a price adjustment roughly equal to the dividend amount, affecting short-term trading decisions.

02

Market read

The upcoming ex-dividend events are relevant primarily for traders and investors focusing on dividend income and short-term price movements within the healthcare and financial sectors.

03

What to watch

Potential upcoming earnings reports or market news could overshadow dividend effects, influencing stock performance beyond the ex-dividend date.

Timing: High, as ex-dividend date is imminent (2026-01-28).

Background

The article highlights upcoming ex-dividend dates for three companies, which is relevant for dividend-focused trading strategies.

Company-level read

Ticker impact

$WSTNeutralHigh confidence
Context

The upcoming ex-dividend date makes WST relevant for dividend-focused trading strategies.

Expected impact

Minor price adjustment, likely a decrease of approximately the dividend amount.

Evidence & confidence

Ex-dividend dates typically cause stock prices to adjust downward by the dividend amount, a well-established market behavior.

$HFWANeutralHigh confidence
Context

Heritage Financial is also trading ex-dividend on 2026-01-28, relevant for dividend investors.

Expected impact

Minor decrease in stock price corresponding to the dividend payout.

Evidence & confidence

Standard ex-dividend price adjustment applies; no unusual market conditions indicated.

$ENTGNeutralHigh confidence
Context

Entegris is scheduled for ex-dividend on 2026-01-28, relevant for dividend strategies.

Expected impact

Expected minor price decline approximately equal to the dividend amount.

Evidence & confidence

Market behavior around ex-dividend dates is predictable; no conflicting signals noted.

Market effects

Potential slight positive sentiment in the healthcare and financial sectors due to dividend payouts.

Limited, primarily affecting stocks in the respective sectors within the US market.

Negligible, as these are US-based companies with localized dividend events.

Counterpoint

Some traders may view the ex-dividend date as an opportunity to buy the stock at a slight discount, expecting recovery post-adjustment.

Key entities

  • West Pharmaceutical Services

    A manufacturer of pharmaceutical packaging and delivery systems.

  • Heritage Financial Corp

    A regional financial services company providing banking and financial products.

  • Entegris Inc

    A provider of advanced materials and process solutions for the semiconductor industry.

Related articles

$ENTGHighAI 9/10

Entegris Q2 Beats at $883M: AI Chip Demand Reaches the Materials Layer

Entegris (NASDAQ: ENTG) reported Q2 2026 revenue of $883.2M and adjusted EPS of $0.93, beating Wall Street estimates across metrics, with revenue up 11% YoY and adjusted EPS up 41%. Advanced Purity Solutions revenue rose to $514.6M and segment margin to 30.3%. Q3 guidance calls for $905M-$935M revenue and adjusted EPS $0.96-$1.04.

$ENTGHigh

ENTEGRIS INC (ENTG): Results of Operations and Financial Condition

ENTEGRIS INC (ENTG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 entgq22026ex991.htm EX-99.1 Document PRESS RELEASE Jeffrey Schnell Vice President, Investor Relations T + 1 201 207 3029 jeffrey.schnell@entegris.com Exhibit 99.1 ENTEGRIS REPORTS RESULTS FOR SECOND QUARTER OF 2026 • Net sales of $883 million. • GAAP diluted EPS of $0.6

$WSTMedAI 8/10

West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary

West Pharmaceutical Services reported Q2 2026 results driven by 16% organic growth in Proprietary Products, including a 29% rise in Biologics. High-Value Product components rose to 49% of revenue. Full-year 2026 organic growth guidance was raised to 10% to 11%, with margin expansion expected. SmartDose divestiture and a May cyber incident were cited.